These data suggest a key role of mitochondrial Ca2+ dysregulation in obesity and diabetes, highlighting the relevance of MCU as a putative therapeutic target for the treatment of these metabolic diseases. This evidence concerns the gene MCU and obesity due to melanocortin 4 receptor deficiency.